Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

Dreyling, M.; Ghielmini, M.; Marcus, R.; Salles, G.; Vitolo, U.; Ladetto, M.
September 2014
Annals of Oncology;Sep2014 Supplement, Vol. 25 Issue suppl_3, piii76
Academic Journal
No abstract available.


Related Articles

  • Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide. Serpe, Loredana; Gallicchio, Margherita; Canaparo, Roberto; Dosio, Franco // Pharmacogenomics & Personalized Medicine;2014, Vol. 7, p31 

    Among the gynecological malignancies, ovarian cancer is the leading cause of mortality in developed countries. Treatment of ovarian cancer is based on surgery integrated with chemotherapy. Platinum-based drugs (cisplatin and carboplatin) comprise the core of first-line chemotherapy for patients...

  • The value of frozen section evaluation in the management of borderline ovarian tumors. Gultekin, Emre; Gultekin, Ozge Elmastas; Cingillioglu, Basak; Sayhan, Sevil; Sanci, Muzaffer; Yildirim, Yusuf // Journal of Cancer Research & Therapeutics;Oct-Dec2011, Vol. 7 Issue 4, p416 

    Purpose: To evaluate the accuracy of a frozen section and to analyze the factors affecting frozen section results in cases of borderline ovarian tumors (BOTs). Materials and Methods: The files and pathological reports of 82 cases diagnosed with BOT at our clinic, between January 1994 and June...

  • Jejunal Metastasis Colliding With a Borderline Tumor in the Ovary. Piana, Simonetta; Giunta, Alessandro; Valli, Riccardo // International Journal of Surgical Pathology;Oct2015, Vol. 23 Issue 7, p567 

    Metastatic adenocarcinomas to the ovary can show morphologically innocuous areas simulating primary benign lesions or borderline tumors. Ruling out a metastasis can be a difficult issue for pathologists, especially when facing with cystic tumors. Because of the important clinical implications of...

  • Advanced ovarian cancer: what should be the standard of care? Goff, Barbara A. // Journal of Gynecologic Oncology;Mar2013, Vol. 24 Issue 1, p83 

    The standard treatment of advanced ovarian cancer is rapidly changing. As we begin to understand that epithelial ovarian cancer is a heterogeneous disease, our treatment strategies are evolving to include novel biologic drugs that specifically exploit altered pathways. Surgery remains an...

  • Carcinosarcoma primario de ovario. Reporte de ocho casos. Montalvo-Esquivel, Gonzalo; Chanona-Vilchis, José Gregorio; Herrera-Gómez, Ángel; Meneses-García, Antelmo Abelardo; Isla-Ortiz, David // Ginecologia y Obstetricia de Mexico;jul2014, Vol. 82 Issue 7, p483 

    Background: The carcinosarcoma, or Mixed Mullerian Malign Tumors, represent 1% of malignant ovarian neoplasm, they are formed by a component epithelium and another mesenquimal malignant both. Objective: Report the experience of the Ginecological Department of the Instituto Nacional de...

  • Targeted therapies and clinical trials in ovarian cancer†. Dancey, J. // Annals of Oncology;Dec2013 Supplement 10, Vol. 24, px59 

    Recent advances in molecular profiling have shown that cancers arising from the ovary are phenotypically and genetically heterogeneous. Within histologies, many mutations in druggable targets are uncommon in frequency but mutations leading to activation of specific signal transduction pathways...

  • Know warning signs for ovarian cancer. ELBENDARY, AL // South County Journal;3/20/2013, Vol. 48 Issue 12, pB2 

    In this article, the author suggests women to get diagnosed for ovarian cancer at an early stage for effective treatment.

  • Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group. Oshita, Takafumi; Itamochi, Hiroaki; Nishimura, Ryuichiro; Numa, Fumitaka; Takehara, Kazuhiro; Hiura, Masamichi; Tanimoto, Hirotoshi; Noma, Jun; Hayase, Ryoji; Murakami, Akihiro; Fujimoto, Hideo; Kanamori, Yasunobu; Kitada, Fuminori; Shitsukawa, Keiji; Nagaji, Makoto; Minagawa, Yukihisa; Fujiwara, Michihisa; Kigawa, Junzo // International Journal of Clinical Oncology;Dec2013, Vol. 18 Issue 6, p1107 

    Background: The therapeutic value of systematic lymphadenectomy for early-stage epithelial ovarian cancer (EOC) is controversial. This study evaluates the survival impact and adverse events of systematic pelvic and para-aortic lymphadenectomy in patients with pT1 and pT2 EOC. Methods: A...

  • The Role of Secondary Surgery in Recurrent Ovarian Cancer. Lorusso, D.; Mancini, M.; Di Rocco, R.; Fontanelli, R.; Raspagliesi, F. // International Journal of Surgical Oncology;2012, p1 

    Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30% and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics